Previous 10 | Next 10 |
Shares of Invitae (NYSE: NVTA) were down 8.6% as of 3:30 p.m. EST on Thursday. This marked the second consecutive session where the stock declined. Invitae hasn't announced any news that would cause its shares to slump. Instead, the stock continued to sink because of a broader marke...
Invitae to Present at the Oppenheimer 31st Annual Healthcare Conference PR Newswire SAN FRANCISCO , March 4, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team wil...
Its been a big, albeit wholly erratic, year for Invitae (NYSE: NVTA) , one of the tech stock winners of 2020. On March 19, 2020, the stock sat at $7.43. In mid-December, it topped $61. Now, after a slide during the last month or so, it closed at $42.01 on Tuesday, March 2. Invit...
Shares of Invitae (NYSE: NVTA) had fallen 6.6% as of 3:13 p.m. EST on Wednesday. The medical genetics company didn't announce any news that would cause the stock to drop. Instead, Invitae's decline today appears to be part of a broader sell-off of high-growth stocks, with the Nasd...
Illumina and its short reading technology pushed the sequencing costs down during the last decade. Long reads and artificial intelligence are improving the sequencing and will likely keep driving the costs lower. Several companies are building business models around these technolo...
Pacific Biosciences of California's long-read instruments can be used by labs to identify the complete coronavirus genome, even after mutations. This ability is playing an important role in virus surveillance. Revenues have been consistently increasing during the last three quarte...
Invitae adds Medneon's risk assessment tools to its education and clinical support offerings -- Easy-to-use software makes it easier for clinicians to use genetics to improve patient care -- PR Newswire SAN FRANCISCO , Feb. 24, 2021 /PRNewswire/ -- Invi...
Genetic testing specialist Invitae (NYSE: NVTA) isn't having a great start to the week. The company's shares fell by more than 10% on Monday, and on Tuesday, it is extending these losses. Invitae's stock was down by 8.4% as of 1:06 p.m. EST today, after falling by as much as 15.2% e...
Invitae is a genetic testing company that aims to deliver packages of medical information to consumers—by the billions. It enjoys reasonable financial strength but has been consistently unprofitable. In addition, it keeps going back to investors for more capital, diluting the v...
Invitae expands capabilities of its advanced clinical chatbot Gia, enhancing telemedicine support for patients and clinicians -- Clinicians can now share test results reports with patients directly, reducing delays and need for in-person visits -- PR Newswire SAN F...
News, Short Squeeze, Breakout and More Instantly...
Labcorp Announces Winning Bid for Select Assets of Invitae PR Newswire Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requires court approval, with confirmation expected on May 6, 2024 ...
Invitae Enters into Agreement with Labcorp for Sale of Business PR Newswire – Labcorp Selected as Winning Bidder in Court-Supervised Sale Process, Subject to Court and Regulatory Approvals – – $239 Million Cash Bid Includes Acquisition of Substantial...
Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance PR Newswire – Study findings to be presented at the 2024 American Society of Breast Surgeons Annual Meeting – SAN FRANCISCO , April 11, 2024 /PRNewsw...